Trevi Therapeutics

Lungs
#Idiopathic pulmonary fibrosis #Lung disease #Phase II trial #Trevi Therapeutics

Drug significantly reduces common cough in IPF patients

Trevi Therapeutics has announced positive topline results from its Phase IIb CORAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF).   The primary endpoint in the CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all… Read More

#News